Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: Prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 4, 2000, Pages 879-884

  Vostrov, Sergey N ^a   Kononenko, Olga V ^a   Lubenko, Irene Y ^a   Zinner, Stephen H ^a,c   Firsov, Alexander A ^a,b  

^a BROWN UNIVERSITY   (United States)

^b Scientific and Technological Centre Lekbiotech   (Russian Federation)

^c MOUNT AUBURN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN;

ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; DRUG HALF LIFE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BACTERIA; CIPROFLOXACIN; COMPUTER SIMULATION; ESCHERICHIA COLI; FLUOROQUINOLONES; HALF-LIFE; HUMANS; KLEBSIELLA PNEUMONIAE; MODELS, BIOLOGICAL; STAPHYLOCOCCUS AUREUS;

EID: 0034101896     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.4.879-884.2000     Document Type: Article

References (17)

1. Bauernfeind, A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40:639-651.
2. Bergan, T., and S. B. Thorsteinsson. 1986. Pharmacokinetics and bioavailability of ciprofloxacin, p. 111-121. In H. C. Neu and H. Weuta (ed.), Proceedings of the 1st International Ciprofloxacin Workshop, Current Clinical Practice series 34. Elsevier Science Publishers B.V. (Excerpta Medica), Amsterdam, The Netherlands.
3. Felmingham, D., M. J. Robbins, K. Ingley, I. Mathias, H. A. Bhogal, G. L. Leakey, G. L. Ridgway, and R. N. Grüneberg. 1997. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J. Antimicrob. Chemother. 39(Suppl. B):43-49.
4. Firsov, A. A., V. M. Chernykh, and S. M. Navashin. 1991. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model. Antimicrob. Agents Chemother. 34:1312-1317.
5. Firsov, A. A., D. Savarino, M. Rubble, D. Gilbert, B. Manzano, A. A. Medeiros, and S. H. Zinner. 1996. Predictors of effect of ampicillin-sulbactam against TEM-1 β-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Antimicrob. Agents Chemother. 40:734-738.
6. Firsov, A. A., A. A. Shevchenko, S. N. Vostrov, and S. H. Zinner. 1998. Inter- and intraquinolone predictors of antimicrobial effect in an in-vitro dynamic model: new insight into a widely used concept. Antimicrob. Agents Chemother. 42:659-665.
7. Firsov, A. A., S. N. Vostrov, O. V. Kononenko, I. Y. Lubenko, and S. H. Zinner. 1999. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model. J. Antimicrob. Chemother. 43:483-490.
8. Firsov, A. A., S. N. Vostrov, A. A. Shevchenko, and G. Cornaglia. 1997. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in-vitro dynamic model. Antimicrob. Agents Chemother. 41:1281-1287.
9. Firsov, A. A., S. N. Vostrov, A. A. Shevchenko, S. H. Zinner, and Y. A. Portnoy. 1998. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. Antimicrob. Agents Chemother. 42:2841-2847.
10. Grasela, D. M., M. Nakashima, T. Uematsu, et al. 1996. Pharmacokinetics of BMS-206584; 200 mg oral dose with concurrent probenecid in humans. Report no. 910058296. Bristol-Myers Squibb Pharmaceutical Research Institute.
11. Grasela, D. M., M. Nakashima, T. Uematsu, et al. 1996. Phase I trial of a single intravenous infusion of BMS-206584 (AM-1155) in healthy male volunteers. Report no. 910058297. Bristol-Myers Squibb Pharmaceutical Research Institute.
12. Grasela, D. M., T. Uematsu, M. Nakashima, et al. 1996. Oral dose phase I study of AM-1155 (BMS-206584). Report no. 910058295. Bristol-Myers Squibb Pharmaceutical Research Institute.
13. Hoffken, G., H. Lode, C. Prinzing, K. Borner, and P. Koeppe. 1985. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob. Agents Chemother. 27:375-379.
14. Schentag, J. J., D. E. Nix, and A. Forrest. 1993. Pharmacodynamics of the fluoroquinolones, p. 259-271. In D. C. Hooper and J. S. Wolfson (ed), Ouinolone antimicrobial agents, 2nd ed. American Society for Microbiology, Washington, D.C.
15. Seftone, A. M., J. P. Maskell, A. M. Rafay, A. Whiley, and J. D. Williams. 1997. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against gram-positive bacteria. J. Antimicrob. Chemother. 39(Suppl. B):57-62.
16. Seifert, H. 1997. Comparative in-vitro activities of trovafloxacin, ciprofloxacin, ofloxacin, and fleroxacin against gram-negative blood isolates. Clin. Microbiol. Infect. 3(Suppl. 2):91.
17. Wise, R., D. Lister, C. A. M. McNulty, D. Griggs, and J. M. Andrews. 1986. The comparative pharmacokinetics of five quinolones. J. Antimicrob. Chemother. 18(Suppl. D):71-81.